{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:04:46Z","timestamp":1793387086212,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["RCDI"],"award-info":[{"award-number":["RCDI"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["P\/C 57009"],"award-info":[{"award-number":["P\/C 57009"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South African National Research Foundation","award":["GUN 109312"],"award-info":[{"award-number":["GUN 109312"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>South Africa, with one of the highest HIV prevalences in the world, introduced the universal test and treat (UTT) programme in September 2016. Barriers to sustained viral suppression may include drug resistance in the pre-treated population, non-adherence, acquired resistance; pharmacokinetics and pharmacodynamics, and concurrent use of alternative treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this review is to highlight potential challenges to achieving sustained viral load suppression in South Africa (SA), a major expectation of the UTT initiative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methodology<\/jats:title><jats:p>Through the PRISMA approach, published articles from South Africa on transmitted drug resistance; adherence to ARV; host genetic factors in drug pharmacokinetics and pharmacodynamics, and interactions between ARV and herbal medicine were searched and reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The level of drug resistance in the pre-treated population in South Africa has increased over the years, although it is heterogeneous across and within Provinces. At least one study has documented a pre-treated population with moderate (&gt;\u20095%) or high (&gt;\u200915%) levels of drug resistance in eight of the nine Provinces. The concurrent use of ARV and medicinal herbal preparation is fairly common in SA, and may be impacting negatively on adherence to ARV. Only few studies have investigated the association between the genetically diverse South African population and pharmacokinetics and pharmacodynamics of ARVs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The increasing levels of drug resistant viruses in the pre-treated population poses a threat to viral load suppression and the sustainability of first line regimens. Drug resistance surveillance systems to track the emergence of resistant viruses, study the burden of prior exposure to ARV and the parallel use of alternative medicines, with the goal of minimizing resistance development and virologic failure are proposed for all the Provinces of South Africa. Optimal management of the different drivers of drug resistance in the pre-treated population, non-adherence, and acquired drug resistance will be beneficial in ensuring sustained viral suppression in at least 90% of those on treatment, a key component of the 90-90-90 strategy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-020-00324-w","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T18:03:54Z","timestamp":1609956234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-272X","authenticated-orcid":false,"given":"Pascal O.","family":"Bessong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontokozo D.","family":"Matume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M.","family":"Tebit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"324_CR1","unstructured":"UNAIDS. Fact sheet\u2014global AIDS update 2019. Unaids. 2019. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed Apr 2020."},{"issue":"6","key":"324_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"issue":"6122","key":"324_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1126\/science.1228160","volume":"339","author":"F Tanser","year":"2013","unstructured":"Tanser F, B\u00e4rnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (80-). 2013;339(6122):966\u201371.","journal-title":"Science (80-)."},{"key":"324_CR4","unstructured":"2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. October 2019. Republic of South Africa National Department of Health. https:\/\/www.knowledgehub.org.za\/elibrary\/2019-art-clinical-guidelines-management-hiv-adults-pregnancy-adolescents-children-infants. Accessed Apr 2020."},{"key":"324_CR5","unstructured":"Mylan launches first fixed-dose combination TLD for people living with HIV in South Africa. 2018. https:\/\/www.mylansa.co.za\/en-za\/news\/2018\/mylan-launches-first-fixed-dose-combination-tld. Accessed Apr 2020."},{"key":"324_CR6","unstructured":"South Africa to introduce state-of-the-art HIV treatment. Unitaid; 2019. https:\/\/unitaid.org\/news-blog\/south-africa-to-introduce-state-of-the-art-hiv-treatment\/#en. Accessed Apr 2020."},{"issue":"Suppl 2","key":"324_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135965350801302S09","volume":"13","author":"V Pillay","year":"2008","unstructured":"Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008;13(Suppl 2):101\u20137.","journal-title":"Antivir Ther"},{"issue":"Suppl 4","key":"324_CR8","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1093\/cid\/cir1017","volume":"54","author":"GM Hunt","year":"2012","unstructured":"Hunt GM, Ledwaba J, Basson AE, Moyes J, Cohen C, Singh B, et al. Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005\u20132009. Clin Infect Dis. 2012;54(Suppl 4):S334\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"324_CR9","doi-asserted-by":"publisher","first-page":"e0166305","DOI":"10.1371\/journal.pone.0166305","volume":"11","author":"K Steegen","year":"2016","unstructured":"Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the First South African National Survey. PLoS ONE. 2016;11(12):e0166305.","journal-title":"PLoS ONE"},{"issue":"3","key":"324_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3851\/IMP3294","volume":"24","author":"GM Hunt","year":"2019","unstructured":"Hunt GM, Ledwaba J, Kalimashe M, Salimo A, Cibane S, Singh B, et al. Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019;24(3):203\u201310.","journal-title":"Antivir Ther"},{"key":"324_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","volume":"9","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara B, Lessells RJ, Rhee S-Y, Giandhari J, Kharsany ABM, Naidoo K, et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000\u20132016: a pooled sequence analysis. EClinicalMedicine. 2019;9:26\u201334.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"324_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3329\/jhpn.v29i4.8444","volume":"29","author":"JM Nwobegahay","year":"2011","unstructured":"Nwobegahay JM, Bessong PO, Masebe TM, Mavhandu LG, Iweriebor BC, Selabe G. Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naive persons visiting a voluntary testing and counselling centre in northeastern South Africa. J Health Popul Nutr. 2011;29(4):303\u20139.","journal-title":"J Health Popul Nutr"},{"issue":"6","key":"324_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1089\/aid.2011.0284","volume":"28","author":"J Manasa","year":"2012","unstructured":"Manasa J, Katzenstein D, Cassol S, Newell M-L, de Oliveira T. Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses. 2012;28(6):558\u201365.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"324_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/jmv.22143","volume":"83","author":"R Parboosing","year":"2011","unstructured":"Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol. 2011;83(9):1508\u201313.","journal-title":"J Med Virol"},{"issue":"2","key":"324_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/cid\/ciy881","volume":"69","author":"A Derache","year":"2019","unstructured":"Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin A-G, Calvez V, et al. Impact of next-generation sequencing defined human immunodeficiency virus pretreatment drug resistance on virological outcomes in the ANRS 12249 treatment-as-prevention trial. Clin Infect Dis. 2019;69(2):207\u201314.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"324_CR16","doi-asserted-by":"publisher","first-page":"e59787","DOI":"10.1371\/journal.pone.0059787","volume":"8","author":"UM Parikh","year":"2013","unstructured":"Parikh UM, Kiepiela P, Ganesh S, Gomez K, Horn S, Eskay K, et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS ONE. 2013;8(4):e59787.","journal-title":"PLoS ONE"},{"issue":"8","key":"324_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/aid.2015.0225","volume":"32","author":"J Manasa","year":"2016","unstructured":"Manasa J, Danaviah S, Lessells R, Elshareef M, Tanser F, Wilkinson E, et al. Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal, South Africa. AIDS Res Hum Retroviruses. 2016;32(8):763\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"324_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/aid.2018.0202","volume":"35","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara B, Kharsany ABM, Lessells RJ, Naidoo K, Rhee S-Y, Manasa J, et al. Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retroviruses. 2019;35(2):129\u201338.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"7","key":"324_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3851\/IMP1416","volume":"14","author":"K-HG Huang","year":"2009","unstructured":"Huang K-HG, Goedhals D, Fryer H, van Vuuren C, Katzourakis A, De Oliveira T, et al. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther. 2009;14(7):975\u201384.","journal-title":"Antivir Ther."},{"issue":"4","key":"324_CR20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350901400414","volume":"14","author":"C Orrell","year":"2009","unstructured":"Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009;14(4):523\u201331.","journal-title":"Antivir Ther"},{"issue":"7","key":"324_CR21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1089\/aid.2008.0028","volume":"24","author":"GB Jacobs","year":"2008","unstructured":"Jacobs GB, Laten A, van Rensburg EJ, Bodem J, Weissbrich B, Rethwilm A, et al. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses. 2008;24(7):1009\u201312.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"324_CR22","doi-asserted-by":"publisher","first-page":"e0188606","DOI":"10.1371\/journal.pone.0188606","volume":"12","author":"J Coetzee","year":"2017","unstructured":"Coetzee J, Hunt G, Jaffer M, Otwombe K, Scott L, Bongwe A, et al. HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: a cross sectional study. PLoS ONE. 2017;12(12):e0188606.","journal-title":"PLoS ONE"},{"issue":"1","key":"324_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1753495X15570994","volume":"8","author":"R Burton","year":"2015","unstructured":"Burton R, Giddy J, Stinson K. Prevention of mother-to-child transmission in South Africa: an ever-changing landscape. Obstet Med. 2015;8(1):5\u201312.","journal-title":"Obstet Med"},{"issue":"11","key":"324_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/QAD.0000000000000261","volume":"28","author":"L Kuhn","year":"2014","unstructured":"Kuhn L, Hunt G, Technau K-G, Coovadia A, Ledwaba J, Pickerill S, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014;28(11):1673\u20138.","journal-title":"AIDS"},{"issue":"12","key":"324_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1097\/QAD.0b013e3283492180","volume":"25","author":"GM Hunt","year":"2011","unstructured":"Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011;25(12):1461\u20139.","journal-title":"AIDS"},{"issue":"4","key":"324_CR26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/INF.0b013e3181c4dada","volume":"29","author":"GU van Zyl","year":"2010","unstructured":"van Zyl GU, Cotton MF, Claassen M, Abrahams C, Preiser W. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa. Pediatr Infect Dis J. 2010;29(4):370\u20131.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"324_CR27","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/cid\/cix1104","volume":"66","author":"N Yeganeh","year":"2018","unstructured":"Yeganeh N, Kerin T, Ank B, Watts DH, Camarca M, Joao EC, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother\u2013infant pairs enrolled in a large perinatal study. Clin Infect Dis. 2018;66(11):1770\u20137.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"324_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/QAD.0b013e328323ad49","volume":"23","author":"NA Martinson","year":"2009","unstructured":"Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, et al. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009;23(7):809\u201316.","journal-title":"AIDS"},{"issue":"7","key":"324_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/aid.2019.0012","volume":"35","author":"J Ledwaba","year":"2019","unstructured":"Ledwaba J, Sayed Y, Pillay V, Morris L, Hunt G. Low frequency of protease inhibitor resistance mutations and insertions in HIV-1 subtype C protease inhibitor-naive sequences. AIDS Res Hum Retroviruses. 2019;35(7):673\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 1","key":"324_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12879-019-4339-y","volume":"19","author":"GM Hunt","year":"2019","unstructured":"Hunt GM, Ledwaba J, Salimo A, Kalimashe M, Dinh T-H, Jackson D, et al. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4\u20138 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011\u201312 and 2012\u201313. BMC Infect Dis. 2019;19(Suppl 1):787.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"324_CR31","doi-asserted-by":"publisher","first-page":"e25426","DOI":"10.1002\/jia2.25426","volume":"23","author":"DL Joseph Davey","year":"2020","unstructured":"Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23(1):e25426. https:\/\/doi.org\/10.1002\/jia2.25426.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"324_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12916-018-1229-x","volume":"16","author":"H Desalegn","year":"2018","unstructured":"Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, et al. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med. 2018;16(1):234. https:\/\/doi.org\/10.1186\/s12916-018-1229-x.","journal-title":"BMC Med."},{"issue":"1","key":"324_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12889-019-7095-4","volume":"19","author":"J Mokaya","year":"2019","unstructured":"Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, et al. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health. 2019;19(1):829. https:\/\/doi.org\/10.1186\/s12889-019-7095-4.","journal-title":"BMC Public Health."},{"key":"324_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.forsciint.2019.04.040","volume":"300","author":"PM Mthembi","year":"2019","unstructured":"Mthembi PM, Mwenesongole EM, Cole MD. Chemical profiling of the street cocktail drug \u2018nyaope\u2019 in South Africa using GC\u2013MS II: stability studies of the cannabinoid, opiate and antiretroviral components during sample storage. Forensic Sci Int. 2019;300:187\u201392.","journal-title":"Forensic Sci Int"},{"key":"324_CR35","unstructured":"Tambe AM, Katerere DR, Bessong POM-RL. Evaluation of efavirenz concentration in plasma and hair as a marker of adherence to ART. In: 20th international conference on AIDS and STIs in Africa. 2019."},{"issue":"4","key":"324_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","volume":"56","author":"GU van Zyl","year":"2011","unstructured":"van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"324_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3851\/IMP2749","volume":"19","author":"RR Moholisa","year":"2014","unstructured":"Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014;19(4):399\u2013406.","journal-title":"Antivir Ther"},{"issue":"2","key":"324_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijantimicag.2016.04.030","volume":"48","author":"R Court","year":"2016","unstructured":"Court R, Gordon M, Cohen K, Stewart A, Gosnell B, Wiesner L, et al. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. Int J Antimicrob Agents. 2016;48(2):158\u201362.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"324_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/aid.2015.0048","volume":"32","author":"CR R\u00f6hrich","year":"2016","unstructured":"R\u00f6hrich CR, Dr\u00f6gem\u00f6ller BI, Ikediobi O, Van Der Merwe L, Grobbelaar N, Wright GEB, et al. CYP2B6\u22176 and CYP2B6\u221718 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African Women. AIDS Res Hum Retroviruses. 2016;32(6):529\u2013528.","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"3","key":"324_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/QAD.0000000000001688","volume":"32","author":"GE Mwasakifwa","year":"2018","unstructured":"Mwasakifwa GE, Moore C, Carey D, Amin J, Penteado P, Losso M, et al. Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018;32(3):357\u201361.","journal-title":"AIDS"},{"issue":"1","key":"324_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4102\/sajhivmed.v20i1.881","volume":"20","author":"J Johnston","year":"2019","unstructured":"Johnston J, Wiesner L, Smith P, Maartens G, Orrell C. Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans. South Afr J HIV Med. 2019;20(1):881.","journal-title":"South Afr J HIV Med"},{"issue":"3","key":"324_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/QAI.0000000000002032","volume":"81","author":"TK Phillips","year":"2019","unstructured":"Phillips TK, Sinxadi P, Abrams EJ, Zerbe A, Orrell C, Hu N-C, et al. A comparison of plasma efavirenz and tenofovir, dried blood spot tenofovir-diphosphate, and self-reported adherence to predict virologic suppression among South African women. J Acquir Immune Defic Syndr. 2019;81(3):311\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"324_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/cid\/ciz209","volume":"70","author":"L Myer","year":"2019","unstructured":"Myer L, Redd AD, Mukonda E, Lynch BA, Phillips TK, Eisenberg A, et al. Antiretroviral adherence, elevated viral load and drug resistant mutations in HIV-infected women initiating treatment in pregnancy: a nested case-control study. Clin Infect Dis. 2019;70(3):501\u20138.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"324_CR44","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1093\/jac\/dkx340","volume":"72","author":"GM Hunt","year":"2017","unstructured":"Hunt GM, Kainne Dokubo E, Takuva S, de Oliveira T, Ledwaba J, Dube N, et al. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017;72(11):3222.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"324_CR45","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1086\/648444","volume":"49","author":"CJ Hoffmann","year":"2009","unstructured":"Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49(12):1928\u201335.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"324_CR46","doi-asserted-by":"publisher","first-page":"e32144","DOI":"10.1371\/journal.pone.0032144","volume":"7","author":"JH Levison","year":"2012","unstructured":"Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS ONE. 2012;7(3):e32144.","journal-title":"PLoS ONE"},{"issue":"18","key":"324_CR47","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1097\/01.aids.0000194807.81917.50","volume":"19","author":"D Chilton","year":"2005","unstructured":"Chilton D, Dervisevic S, Pillay D, Rider A, Copas A, Miller RF, et al. Determinants of HIV drug resistance mutations in plasma virus after treatment interruption. AIDS. 2005;19(18):2174\u20135. https:\/\/doi.org\/10.1097\/01.aids.0000194807.81917.50.","journal-title":"AIDS"},{"key":"324_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijid.2020.02.004","volume":"93","author":"NY Chen","year":"2020","unstructured":"Chen NY, Kao SW, Liu ZH, Wu TS, Tsai CL, Lin HH, et al. Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection. Int J Infect Dis. 2020;93:182\u201391. https:\/\/doi.org\/10.1016\/j.ijid.2020.02.004.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"324_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0956462414535206","volume":"26","author":"EB Wroe","year":"2015","unstructured":"Wroe EB, Hedt-Gauthier BL, Franke MF, Nsanzimana S, Turinimana JB, Drobac P. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. Int J STD AIDS. 2015;26(4):257\u201361. https:\/\/doi.org\/10.1177\/0956462414535206.","journal-title":"Int J STD AIDS"},{"issue":"8","key":"324_CR50","doi-asserted-by":"publisher","first-page":"e25586","DOI":"10.1002\/jia2.25586","volume":"23","author":"LT Matthews","year":"2020","unstructured":"Matthews LT, Orrell C, Bwana MB, Tsai AC, Psaros C, Asiimwe S, et al. Adherence to HIV antiretroviral therapy among pregnant and postpartum women during the Option B+ era: 12-month cohort study in urban South Africa and rural Uganda. J Int AIDS Soc. 2020;23(8):e25586. https:\/\/doi.org\/10.1002\/jia2.25586.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"324_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/09540121.2014.994471","volume":"27","author":"S Dewing","year":"2015","unstructured":"Dewing S, Mathews C, Lurie M, Kagee A, Padayachee T, Lombard C. Predictors of poor adherence among people on antiretroviral treatment in Cape Town, South Africa: a case\u2013control study. AIDS Care. 2015;27(3):342\u20139.","journal-title":"AIDS Care"},{"issue":"3","key":"324_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2989\/16085906.2016.1210656","volume":"15","author":"S Purchase","year":"2016","unstructured":"Purchase S, Cunningham J, Esser M, Skinner D. Keeping kids in care: virological failure in a paediatric antiretroviral clinic and suggestions for improving treatment outcomes. AJAR Afr J AIDS Res. 2016;15(3):301\u20139.","journal-title":"AJAR Afr J AIDS Res"},{"key":"324_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugalcdep.2016.07.028","volume":"167","author":"KM Sileo","year":"2016","unstructured":"Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. Drug Alcohol Depend. 2016;167:103\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"324_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/17290376.2018.1529613","volume":"15","author":"S Ramlagan","year":"2018","unstructured":"Ramlagan S, Matseke G, Rodriguez VJ, Jones DL, Peltzer K, Ruiter RAC, et al. Determinants of disclosure and non-disclosure of HIV-positive status, by pregnant women in rural South Africa. SAHARA J J Soc Asp HIV AIDS Res Alliance. 2018;15(1):155\u201363.","journal-title":"SAHARA J J Soc Asp HIV AIDS Res Alliance"},{"issue":"4","key":"324_CR55","doi-asserted-by":"publisher","first-page":"e1160","DOI":"10.1002\/hpm.2602","volume":"33","author":"M Guillon","year":"2018","unstructured":"Guillon M. Success factors for universal access to antiretroviral treatments in South Africa. Int J Health Plann Manag. 2018;33(4):e1160\u201378.","journal-title":"Int J Health Plann Manag"},{"issue":"11","key":"324_CR56","doi-asserted-by":"publisher","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.","journal-title":"PLoS Med"},{"issue":"2","key":"324_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0009-9236(03)00151-6","volume":"74","author":"PK Chelule","year":"2003","unstructured":"Chelule PK, Gordon M, Palanee T, Page T, Mosam A, Coovadia HM, et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther. 2003;74(2):195\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"324_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2217\/pgs.16.14","volume":"17","author":"B Mpeta","year":"2016","unstructured":"Mpeta B, Kampira E, Castel S, Mpye KL, Soko ND, Wiesner L, et al. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016;17(7):679\u201390.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"324_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/omi.2018.0117","volume":"22","author":"KS O\u2019Connell","year":"2018","unstructured":"O\u2019Connell KS, Swart M, McGregor NW, Dandara C, Warnich L. Pharmacogenetics of antiretroviral drug response and pharmacokinetic variations in indigenous South African populations. OMI J Integr Biol. 2018;22(9):589\u201397.","journal-title":"OMI J Integr Biol"},{"issue":"8","key":"324_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","volume":"23","author":"M Swart","year":"2013","unstructured":"Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients. Pharmacogenet Genomics. 2013;23(8):415\u201327.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"324_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bcp.12590","volume":"80","author":"PZ Sinxadi","year":"2015","unstructured":"Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. 2015;80(1):146\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"324_CR62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00228-011-1148-7","volume":"68","author":"M Viljoen","year":"2012","unstructured":"Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012;68(4):339\u201347.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"324_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1089\/omi.2017.0078","volume":"21","author":"R Reay","year":"2017","unstructured":"Reay R, Dandara C, Viljoen M, Rheeders M. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study. OMICS. 2017;21(8):465\u201373.","journal-title":"OMICS"},{"issue":"1","key":"324_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1155\/2012\/453479","volume":"32","author":"TM Masebe","year":"2012","unstructured":"Masebe TM, Bessong PO, Nwobegahay J, Ndip RN, Meyer D. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients. Dis Markers. 2012;32(1):43\u201350.","journal-title":"Dis Markers"},{"issue":"5","key":"324_CR65","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/jhg.2009.20","volume":"54","author":"J Parathyras","year":"2009","unstructured":"Parathyras J, Gebhardt S, Hillermann-Rebello R, Grobbelaar N, Venter M, Warnich L. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet. 2009;54(5):261\u20135.","journal-title":"J Hum Genet"},{"issue":"5","key":"324_CR66","doi-asserted-by":"publisher","first-page":"e000895","DOI":"10.1136\/bmjgh-2018-000895","volume":"3","author":"PB James","year":"2018","unstructured":"James PB, Wardle J, Steel A, Adams J. Traditional, complementary and alternative medicine use in Sub-Saharan Africa: a systematic review. BMJ Glob Health. 2018;3(5):e000895.","journal-title":"BMJ Glob Health"},{"key":"324_CR67","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12906-016-1101-5","volume":"16","author":"M Nlooto","year":"2016","unstructured":"Nlooto M, Naidoo P. Traditional, complementary and alternative medicine use by HIV patients a decade after public sector antiretroviral therapy roll out in South Africa: a cross sectional study. BMC Complement Altern Med. 2016;16:128.","journal-title":"BMC Complement Altern Med"},{"key":"324_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.trstmh.2007.11.009","volume":"102","author":"PO Bessong","year":"2008","unstructured":"Bessong PO. Issues surrounding the use of herbal therapies for AIDS in endemic regions. Trans R Soc Trop Med Hyg. 2008;102:209.","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"3","key":"324_CR69","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/13548500600621511","volume":"12","author":"DA Babb","year":"2007","unstructured":"Babb DA, Pemba L, Seatlanyane P, Charalambous S, Churchyard GJ, Grant AD. Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med. 2007;12(3):314\u201320.","journal-title":"Psychol Health Med"},{"issue":"2","key":"324_CR70","first-page":"125","volume":"7","author":"K Peltzer","year":"2010","unstructured":"Peltzer K, Friend-du Preez N, Ramlagan S, Fomundam H, Anderson J, Preez NF, et al. Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in Kwazulu-Natal, South Africa. Afr J Tradit Complement Altern Med. 2010;7(2):125\u201337.","journal-title":"Afr J Tradit Complement Altern Med"},{"issue":"4","key":"324_CR71","first-page":"337","volume":"8","author":"K Peltzer","year":"2011","unstructured":"Peltzer K, Preez NF, Ramlagan S, Fomundam H, Anderson J, Chanetsa L. Antiretrovirals and the use of traditional, complementary and alternative medicine by HIV patients in Kwazulu-Natal, South Africa: a longitudinal study. Afr J Tradit Complement Altern Med AJTCAM. 2011;8(4):337\u201345.","journal-title":"Afr J Tradit Complement Altern Med AJTCAM"},{"issue":"7","key":"324_CR72","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/09540121.2017.1417527","volume":"30","author":"D Evans","year":"2018","unstructured":"Evans D, Dahlberg S, Berhanu R, Sineke T, Govathson C, Jonker I, et al. Social and behavioral factors associated with failing second-line ART\u2014results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa. AIDS Care Psychol Socio Med Asp AIDS\/HIV. 2018;30(7):863\u201370.","journal-title":"AIDS Care Psychol Socio Med Asp AIDS\/HIV"},{"issue":"4","key":"324_CR73","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4314\/ajtcam.v5i4.31292","volume":"5","author":"K Peltzer","year":"2008","unstructured":"Peltzer K, Mngqundaniso N. Patients consulting traditional health practioners in the context of HIV\/AIDS in urban areas in KwaZulu-Natal, South Africa. Afr J Tradit Complement Altern Med. 2008;5(4):370\u20139.","journal-title":"Afr J Tradit Complement Altern Med"},{"issue":"4","key":"324_CR74","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4314\/ajtcam.v9i4.6","volume":"9","author":"TR Puoane","year":"2012","unstructured":"Puoane TR, Hughes GD, Uwimana J, Johnson Q, Folk WR. Why HIV positive patients on antiretroviral treatment and\/or cotrimoxazole prophylaxis use traditional medicine: perceptions of health workers, traditional healers and patients: a study in two provinces of South Africa. Afr J Tradit Complement Altern Med. 2012;9(4):495\u2013502.","journal-title":"Afr J Tradit Complement Altern Med"},{"issue":"8","key":"324_CR75","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1080\/09540121.2016.1164292","volume":"28","author":"KB Loeliger","year":"2016","unstructured":"Loeliger KB, Niccolai LM, Mtungwa LN, Moll A, Shenoi SV. Antiretroviral therapy initiation and adherence in rural South Africa: community health workers\u2019 perspectives on barriers and facilitators. AIDS Care. 2016;28(8):982\u201393.","journal-title":"AIDS Care"},{"issue":"1","key":"324_CR76","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.4314\/ahs.v19i1.15","volume":"19","author":"C Burman","year":"2019","unstructured":"Burman C, Aphane M. Improved adherence to anti-retroviral therapy among traditionalists: reflections from rural South Africa. Afr Health Sci. 2019;19(1):1422\u201332.","journal-title":"Afr Health Sci"},{"key":"324_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-017-0140-4","volume":"14","author":"TG Monera-Penduka","year":"2017","unstructured":"Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CFB. Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Res Ther. 2017;14:12.","journal-title":"AIDS Res Ther."},{"issue":"12\u201313","key":"324_CR78","first-page":"895","volume":"84","author":"K Havenga","year":"2018","unstructured":"Havenga K, Abay E, Wiesner L, Viljoen A, Steyn D, Hamman J. The in vitro and in vivo effects of Hypoxis hemerocallidea on indinavir pharmacokinetics: modulation of efflux. Planta Med. 2018;84(12\u201313):895\u2013901.","journal-title":"Planta Med"},{"key":"324_CR79","doi-asserted-by":"publisher","first-page":"324618","DOI":"10.1155\/2013\/324618","volume":"2013","author":"AC M\u00fcller","year":"2013","unstructured":"M\u00fcller AC, Skinner MF, Kanfer I. Effect of the African traditional medicine, Sutherlandia frutescens, on the bioavailability of the antiretroviral protease inhibitor, atazanavir. Evid Based Complement Altern Med. 2013;2013:324618.","journal-title":"Evid Based Complement Altern Med"},{"issue":"8","key":"324_CR80","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/bdd.775","volume":"32","author":"AC Muller","year":"2011","unstructured":"Muller AC, Kanfer I. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm Drug Dispos. 2011;32(8):458\u201370.","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"324_CR81","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1517\/17425255.2014.920321","volume":"10","author":"C Calitz","year":"2014","unstructured":"Calitz C, Steenekamp JH, Steyn JD, Gouws C, Viljoen JM, Hamman JH. Impact of traditional African medicine on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2014;10(7):991\u20131003.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"324_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa116","author":"TA Crowell","year":"2020","unstructured":"Crowell TA, Danboise B, Parikh A, Esber A, Dear N, Coakley P, et al. Pre-treatment and acquired antiretroviral drug resistance among persons living with HIV in four African Countries. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa116.","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc Am."},{"issue":"6","key":"324_CR83","doi-asserted-by":"publisher","first-page":"e90845","DOI":"10.1371\/journal.pone.0090845","volume":"9","author":"GB Jacobs","year":"2014","unstructured":"Jacobs GB, Wilkinson E, Isaacs S, Spies G, de Oliveira T, Seedat S, et al. HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa. PLoS ONE. 2014;9(6):e90845.","journal-title":"PLoS ONE"},{"issue":"11","key":"324_CR84","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1007\/s10461-015-1056-4","volume":"19","author":"BS Mensch","year":"2015","unstructured":"Mensch BS, Gorbach PM, Kelly C, Kiepiela P, Gomez K, Ramjee G, et al. Characteristics associated with HIV drug resistance among women screening for an HIV prevention trial in KwaZulu-Natal, South Africa. AIDS Behav. 2015;19(11):2076\u201386. https:\/\/doi.org\/10.1007\/s10461-015-1056-4.","journal-title":"AIDS Behav"},{"issue":"8","key":"324_CR85","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/rcm.8077","volume":"32","author":"J Johnston","year":"2018","unstructured":"Johnston J, Orrell C, Smith P, Joubert A, Wiesner L. A validated liquid chromatography\/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients. Rapid Commun Mass Spectrom. 2018;32(8):657\u201364.","journal-title":"Rapid Commun Mass Spectrom."},{"issue":"1","key":"324_CR86","first-page":"742","volume":"18","author":"M Dheda","year":"2017","unstructured":"Dheda M. Herbal slimming formulations or remedies interact with antiretroviral therapy. South Afr J HIV Med. 2017;18(1):742.","journal-title":"South Afr J HIV Med"},{"issue":"4","key":"324_CR87","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.4314\/ahs.v16i4.30","volume":"16","author":"M Sibanda","year":"2016","unstructured":"Sibanda M, Nlooto MM, Naidoo P. Concurrent use of Antiretroviral and African traditional medicines amongst people living with HIV\/AIDS (PLWA) in the eThekwini Metropolitan area of KwaZulu Natal. Afr Health Sci. 2016;16(4):1118\u201330.","journal-title":"Afr Health Sci"},{"issue":"3","key":"324_CR88","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/ph8030637","volume":"8","author":"NE Thomford","year":"2015","unstructured":"Thomford NE, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D, et al. Pharmacogenomics implications of using herbal medicinal plants on african populations in health transition. Pharmaceuticals (Basel). 2015;8(3):637\u201363.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"324_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/17441692.2014.967709","volume":"10","author":"HA Belisle","year":"2015","unstructured":"Belisle HA, Hennink M, Ordonez CE, John S, Ngubane-Joye E, Hampton J, et al. Concurrent use of traditional medicine and ART: Perspectives of patients, providers and traditional healers in Durban, South Africa. Glob Public Health. 2015;10(1):71\u201387.","journal-title":"Glob Public Health"},{"issue":"2","key":"324_CR90","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/dmd.112.049593","volume":"41","author":"PS Fasinu","year":"2013","unstructured":"Fasinu PS, Gutmann H, Schiller H, James A-D, Bouic PJ, Rosenkranz B. The potential of Sutherlandia frutescens for herb\u2013drug interaction. Drug Metab Dispos. 2013;41(2):488\u201397.","journal-title":"Drug Metab Dispos"},{"key":"324_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-182","author":"M Moshabela","year":"2012","unstructured":"Moshabela M, Schneider H, Silal SP, Cleary SM. Factors associated with patterns of plural healthcare utilization among patients taking antiretroviral therapy in rural and urban South Africa: a cross-sectional study. BMC Health Serv Res. 2012. https:\/\/doi.org\/10.1186\/1472-6963-12-182.","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"324_CR92","first-page":"16","volume":"34","author":"JM Shuster","year":"2009","unstructured":"Shuster JM, Sterk CE, Frew PM, del Rio C. The cultural and community-level acceptance of antiretroviral therapy (ART) among traditional healers in Eastern Cape. South Africa J Community Health. 2009;34(1):16\u201322.","journal-title":"South Africa J Community Health"},{"key":"324_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-63","author":"M Dahab","year":"2008","unstructured":"Dahab M, Charalambous S, Hamilton R, Fielding K, Kielmann K, Churchyard GJ, et al. \u201cThat is why I stopped the ART\u2019\u2019: patients\u2019 and providers\u2019 perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health. 2008. https:\/\/doi.org\/10.1186\/1471-2458-8-63.","journal-title":"BMC Public Health."},{"issue":"3","key":"324_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4314\/ajtcam.v4i3.31219","volume":"4","author":"N Malangu","year":"2007","unstructured":"Malangu N. Self-reported use of traditional, complementary and over-the-counter medicines by HIV-infected patients on antiretroviral therapy in Pretoria, South Africa. Afr J Tradit Complement Altern Med AJTCAM. 2007;4(3):273\u20138.","journal-title":"Afr J Tradit Complement Altern Med AJTCAM"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-020-00324-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T20:12:22Z","timestamp":1670703142000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00324-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00324-w","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. The study did not require an independent review because no human subjects were involved, and no personal identifiers were used.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"POB and NDM declare no conflict of interest. DMT is an Associate Editor for AIDS Research and Therapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}